DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Unlocking strategic investment opportunities in a key Eurasian economy
21/05/2025
CreditAccess expects recovery amid improving PAR performance
21/05/2025
Gold trading hits $298 billion daily in March, says WGC report
21/05/2025
Gold rallies Rs 1,910 to Rs 98,450/10 g amid global uncertainty
21/05/2025
These 5 stocks show consistent growth in quarterly EPS
21/05/2025
Revolt in Pakistan's Sindh : Highway blocked, minister's house torched, two dead as protest over Indus canal project spirals out of (...)
21/05/2025
